Regulus Therapeutics (NASDAQ:RGLS) Shares Cross Above 200 Day Moving Average of $1.74

Regulus Therapeutics Inc. (NASDAQ:RGLS) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.74 and traded as high as $2.08. Regulus Therapeutics shares last traded at $2.01, with a volume of 219,068 shares.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on RGLS shares. Leerink Partnrs reaffirmed an “outperform” rating on shares of Regulus Therapeutics in a research report on Monday, March 18th. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Regulus Therapeutics in a report on Monday, May 6th. Wells Fargo & Company boosted their price objective on shares of Regulus Therapeutics from $2.00 to $3.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 13th. StockNews.com started coverage on Regulus Therapeutics in a research note on Tuesday, April 16th. They set a “sell” rating on the stock. Finally, SVB Leerink began coverage on Regulus Therapeutics in a report on Monday, March 18th. They issued an “outperform” rating and a $6.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $7.25.

Regulus Therapeutics Price Performance

The company has a market cap of $125.70 million, a P/E ratio of -1.29 and a beta of 1.59. The stock’s 50-day moving average is $2.45 and its two-hundred day moving average is $1.75.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.40). On average, analysts predict that Regulus Therapeutics Inc. will post -0.59 EPS for the current year.

Institutional Trading of Regulus Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Victory Capital Management Inc. boosted its stake in shares of Regulus Therapeutics by 5.3% during the 3rd quarter. Victory Capital Management Inc. now owns 233,207 shares of the biopharmaceutical company’s stock worth $322,000 after acquiring an additional 11,701 shares during the last quarter. FMR LLC raised its stake in shares of Regulus Therapeutics by 32.4% in the third quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock worth $4,033,000 after buying an additional 716,000 shares during the period. Vivo Capital LLC bought a new position in shares of Regulus Therapeutics during the 1st quarter valued at approximately $14,400,000. CVI Holdings LLC purchased a new stake in Regulus Therapeutics in the 1st quarter worth approximately $4,050,000. Finally, Vanguard Group Inc. lifted its holdings in Regulus Therapeutics by 158.4% during the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock valued at $2,132,000 after purchasing an additional 453,784 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.